Live feed14:05:04·806dNEWSReleasevia QuantisnowCymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: AnalystByQuantisnow·Wall Street's wire, on your screen.CBAY· CymaBay Therapeutics Inc.GILD· Gilead Sciences Inc.ICPT· Intercept Pharmaceuticals Inc.Health Care
